keyword
MENU ▼
Read by QxMD icon Read
search

Refractory follicular lymphoma

keyword
https://www.readbyqxmd.com/read/30112190/systematic-review-of-therapy-used-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma
#1
REVIEW
Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Meredith Hoog, Tarun Bhagnani, Jill Bell, Yaping Shou
To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012-May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse...
July 2018: Future Science OA
https://www.readbyqxmd.com/read/30060083/venetoclax-bendamustine-and-rituximab-in-patients-with-relapsed-or-refractory-nhl-a-phase-1b-dose-finding-study
#2
S de Vos, L J Swinnen, D Wang, E Reid, N Fowler, J Cordero, M Dunbar, S H Enschede, C Nolan, A M Petrich, J A Ross, A H Salem, M Verdugo, S Agarwal, L Zhou, M Kozloff, L J Nastoupil, C R Flowers
Background: Venetoclax is a selective, potent inhibitor of the anti-apoptotic BCL-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine-rituximab (BR) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Patients and methods: BR was given for 6 cycles at standard doses. Intermittent and continuous oral venetoclax administration was explored at 50mg-1200mg daily doses...
July 28, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30042825/tolerability-of-obinutuzumab-therapy-in-patients-with-rituximab-relapsed-refractory-b-cell-malignancies-a-retrospective-single-center-cohort-study
#3
Theo Pirich, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, Josef Singer
Background & Aim: In randomised clinical trials, the type II anti-CD20 antibody obinutuzumab has been shown to be more effective than rituximab for therapy of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). However, this enhanced efficacy was linked with elevated rates of high-grade adverse events. The aim of this study was to assess the tolerability and toxicity profile of obinutuzumab treatment in routine patients with CLL and FL, of whom the majority had experienced toxicity or resistance to rituximab...
July 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29980507/positive-results-for-tazemetostat-in-follicular-lymphoma
#4
(no author information available yet)
A recently reported clinical trial indicates that the EZH2 inhibitor tazemetostat is effective against relapsed or refractory follicular lymphoma. Three of 28 patients with EZH2 mutations had complete responses, and 17 had partial responses.
July 6, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29974035/cancer-immunotherapy-and-the-immune-response-in-follicular-lymphoma
#5
REVIEW
Frank Stenner, Christoph Renner
Follicular lymphoma (FL) is the most frequent indolent lymphoma in the Western world and is characterized in almost all cases by the t(14;18) translocation that results in overexpression of BCL2, an anti-apoptotic protein. The entity includes a spectrum of subentities that differ from an indolent to a very aggressive growth pattern. As a consequence, treatment can include watch & wait up to intensive chemotherapy including allogeneic stem cell transplantation. The immune cell microenvironment has been recognized as a major driver of outcome of FL patients and gene expression profiling has identified a clinically relevant gene expression signature that classifies an immune response to the lymphoma cells...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29963527/long-term-control-of-refractory-follicular-lymphoma-after-treatment-of-secondary-acute-promyelocytic-leukemia-with-arsenic-trioxide-as-2-o-3-and-all-trans-retinoic-acid-atra
#6
Preetesh Jain, Sergej Konoplev, Ohad Benjamini, Jorge Romagura, Jan A Burger
No abstract text is available yet for this article.
June 2018: Blood Research
https://www.readbyqxmd.com/read/29934061/an-evidence-based-review-of-anti-cd20-antibody-containing-regimens-for-the-treatment-of-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-diffuse-large-b-cell-lymphoma-or-follicular-lymphoma
#7
REVIEW
Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Pilar Nava-Parada
Combination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies; however, the available comparative clinical evidence is limited. The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment approach...
August 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29923173/cost-effectiveness-of-obinutuzumab-in-combination-with-bendamustine-followed-by-obinutuzumab-maintenance-versus-bendamustine-alone-in-treatment-of-patients-with-rituximab-refractory-follicular-lymphoma-in-norway
#8
Fredrik Salvesen Haukaas, Audun Ohna, Tania Krivasi
AIMS: To evaluate the cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinituzumab maintenance (Obin-Benda) compared to bendamustine alone (Benda) in patients with refractory follicular lymphoma (FL) in a Norwegian setting. METHODS: A three-state area-under-the-curve (AUC) model was developed. The states included were progression-free-survival (PFS), progressed disease (PD), and death. Each state had costs and utilities assigned to it...
June 19, 2018: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/29909914/car-t-cell-therapy-for-b-cell-lymphomas
#9
REVIEW
Julio C Chavez, Frederick L Locke
B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas...
June 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29898619/cost-effectiveness-of-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-monotherapy-for-the-treatment-of-follicular-lymphoma-patients-who-relapse-after-or-are-refractory-to-a-rituximab-containing-regimen-in-the-us
#10
Gregory F Guzauskas, Anthony Masaquel, Carolina Reyes, Coen Bernaards, Tania Krivasi, David L Veenstra
AIMS: Obinutuzumab (GA101, G) was approved in February 2016 by the US Food and Drug Administration to treat follicular lymphoma (FL) patients who relapsed after, or are refractory to (R/R), a rituximab-containing regimen (R/R-rituximab). In the GADOLIN trial, R/R-rituximab patients who received G plus bendamustine (B) followed by G-monotherapy (G + B) for up to 2 years had significantly improved progression-free survival and overall survival compared to patients receiving B-monotherapy...
July 6, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29895903/integrated-dna-rna-targeted-genomic-profiling-of-diffuse-large-b-cell-lymphoma-using-a-clinical-assay
#11
Andrew M Intlekofer, Erel Joffe, Connie L Batlevi, Patrick Hilden, Jie He, Venkatraman E Seshan, Andrew D Zelenetz, M Lia Palomba, Craig H Moskowitz, Carol Portlock, David J Straus, Ariela Noy, Steven M Horwitz, John F Gerecitano, Alison Moskowitz, Paul Hamlin, Matthew J Matasar, Anita Kumar, Marcel R van den Brink, Kristina M Knapp, Janine D Pichardo, Michelle K Nahas, Sally E Trabucco, Tariq Mughal, Amanda R Copeland, Elli Papaemmanuil, Mathai Moarii, Ross L Levine, Ahmet Dogan, Vincent A Miller, Anas Younes
We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma)...
June 12, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29851937/management-of-relapsed-refractory-follicular-lymphoma
#12
Peter Martin
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851546/ibrutinib-as-treatment-for-patients-with-relapsed-refractory-follicular-lymphoma-results-from-the-open-label-multicenter-phase-ii-dawn-study
#13
Ajay K Gopal, Stephen J Schuster, Nathan H Fowler, Judith Trotman, Georg Hess, Jing-Zhou Hou, Abdulraheem Yacoub, Michael Lill, Peter Martin, Umberto Vitolo, Andrew Spencer, John Radford, Wojciech Jurczak, James Morton, Dolores Caballero, Sanjay Deshpande, Gary J Gartenberg, Shean-Sheng Wang, Rajendra N Damle, Michael Schaffer, Sriram Balasubramanian, Jessica Vermeulen, Bruce D Cheson, Gilles Salles
Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee-assessed overall response rate (ORR; complete response plus partial response)...
May 31, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29843792/safety-and-efficacy-of-obinutuzumab-in-chinese-patients-with-b-cell-lymphomas-a-secondary-analysis-of-the-gershwin-trial
#14
Yan Qin, Yuqin Song, Zhixiang Shen, Xin Du, Wei Ji, Wanling Hsu, Jun Zhu, Yuankai Shi
BACKGROUND: Patients with relapsed/refractory B-cell lymphomas have limited treatment options. GERSHWIN is an open-label, single-arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20+ relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL). The primary outcome measure of pharmacokinetics has been previously reported. We now present data on the secondary endpoint measures (e...
May 30, 2018: Cancer communications
https://www.readbyqxmd.com/read/29796824/follicular-lymphoma-past-present-and-future
#15
REVIEW
Melody R Becnel, Loretta J Nastoupil
Even in the modern era, follicular lymphoma (FL) remains largely an incurable but treatable disease with both standard and novel treatment modalities. Despite the abundance of efficacious treatment modalities currently available, there is no universally agreed upon standard approach to treatment for patients with FL, particularly in the relapsed/refractory (R/R) setting. There is an increasing need for better tools to risk-stratify patients and to identify those likely to experience relapse early. Additionally, the use of gene expression profiling and next-generation sequencing techniques in recent years has led to a wealth of knowledge regarding the molecular drivers of lymphomagenesis; however, much of this knowledge is not currently applicable on a day to day basis in the clinic setting...
May 24, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29771253/axicabtagene-ciloleucel-for-the-treatment-of-relapsed-refractory-b-cell-non-hodgkin-s-lymphomas
#16
REVIEW
P Sharma, G T King, S S Shinde, E Purev, A Jimeno
B-cell non-Hodgkin's lymphomas are the most common hematological malignancies, which despite improvements in chemo-immunotherapy, carry a uniformly poor prognosis in the relapsed/refractory setting. CD19 is an antigen expressed on the surface of most malignancies arising from the B cells, and adoptive transfer of anti-CD19 chimeric antigen receptor (CAR)-expressing T cells has been shown to be effective in treating these B-cell malignancies. Axicabtagene ciloleucel (axi-cel, KTE-C19) is an autologous anti-CD19 CAR T-cell therapy which has shown high overall response rates and a manageable safety profile in patients with relapsed or refractory B-cell malignancies who lack effective and curative treatment options...
March 2018: Drugs of Today
https://www.readbyqxmd.com/read/29761908/rituximab-maintenance-therapy-of-follicular-lymphoma-in-clinical-practice
#17
Ulrich Dührsen, Stefanie Broszeit-Luft, Annette Dieing, Andreas Lück, Piotr Porowski, Marcel Reiser, Ulrike Schwinger, Sandra Klawitter, Katja Krumm, Kathleen Jentsch-Ullrich
Standard of care for patients with symptomatic, advanced-stage follicular lymphoma (FL) is rituximab-containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how efficacy and safety data from randomized controlled trials translate into clinical practice in Germany. Both treatment-naïve and relapsed/refractory patients with FL, who responded to rituximab-containing induction and were scheduled for rituximab maintenance, were observed for 24 months...
May 15, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29695516/phase-1-study-of-the-pi3k%C3%AE-inhibitor-incb040093-%C3%A2-jak1-inhibitor-itacitinib-in-relapsed-refractory-b-cell-lymphoma
#18
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, Catherine S Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M Barr
Because both phosphatidylinositol 3-kinase δ (PI3Kδ) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3Kδ inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas...
July 19, 2018: Blood
https://www.readbyqxmd.com/read/29623080/proapoptotic-bim-impacts-b-lymphoid-homeostasis-by-limiting-the-survival-of-mature-b-cells-in-a-cell-autonomous-manner
#19
Rui Liu, Ashleigh King, Philippe Bouillet, David M Tarlinton, Andreas Strasser, Jörg Heierhorst
The proapoptotic BH3-only protein BIM ( Bcl2l11 ) plays key roles in the maintenance of multiple hematopoietic cell types. In mice, germline knockout or conditional pan-hematopoietic deletion of Bim results in marked splenomegaly and significantly increased numbers of B cells. However, it has remained unclear whether these abnormalities reflect the loss of cell-intrinsic functions of BIM within the B lymphoid lineage and, if so, which stages in the lifecycle of B cells are most impacted by the loss of BIM. Here, we show that B lymphoid-specific conditional deletion of Bim during early development (i...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29594951/obinutuzumab-with-bendamustine-for-treating-follicular-lymphoma-refractory-to-rituximab-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#20
REVIEW
Rachid Rafia, Abdullah Pandor, Sarah Davis, John W Stevens, Sue Harnan, Mark Clowes, Youssef Sorour, Robert Cutting
As part of its single technology appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of obinutuzumab (Roche) to submit evidence on its clinical and cost effectiveness when used in combination with bendamustine in patients with follicular lymphoma (FL) refractory to rituximab. The Evidence Review Group (ERG), the School of Health and Related Research Technology Appraisal Group at the University of Sheffield, produced a document summarising the key points from the company submission alongside a critical review...
March 28, 2018: PharmacoEconomics
keyword
keyword
169707
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"